LON:ABC

Abcam Share Forecast, Price & News

GBX 1,500
+14.00 (+0.94 %)
(As of 09/16/2021 12:00 AM ET)
Add
Compare
Today's Range
1,485
1,516
50-Day Range
1,265
1,549
52-Week Range
1,142
1,740
Volume300,664 shs
Average Volume408,697 shs
Market Capitalization£3.40 billion
P/E RatioN/A
Dividend Yield0.91%
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ABC News and Ratings via Email

Sign-up to receive the latest news and ratings for Abcam and its competitors with MarketBeat's FREE daily newsletter.


Abcam logo

About Abcam

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.76 out of 5 stars

Analyst Opinion: 1.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Abcam (LON:ABC) Frequently Asked Questions

Is Abcam a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abcam in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Abcam stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABC, but not buy additional shares or sell existing shares.
View analyst ratings for Abcam
or view top-rated stocks.

What stocks does MarketBeat like better than Abcam?

Wall Street analysts have given Abcam a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Abcam wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Abcam's stock price been impacted by COVID-19?

Abcam's stock was trading at GBX 1,140 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ABC shares have increased by 31.6% and is now trading at GBX 1,500.
View which stocks have been most impacted by COVID-19
.

Is Abcam a good dividend stock?

Abcam pays an annual dividend of GBX 0.04 per share and currently has a dividend yield of 0.91%.
View Abcam's dividend history.

What price target have analysts set for ABC?

5 brokers have issued twelve-month target prices for Abcam's stock. Their forecasts range from GBX 1,300 to GBX 1,530. On average, they expect Abcam's stock price to reach GBX 1,442 in the next twelve months. This suggests that the stock has a possible downside of 3.9%.
View analysts' price targets for Abcam
or view top-rated stocks among Wall Street analysts.

Who are Abcam's key executives?

Abcam's management team includes the following people:
  • Mr. Alan Thomas Hirzel BS, MS, MBA, CEO & Exec. Director (Age 53, Pay $1.05M)
  • Mr. Michael Shaun Baldock, CFO & Director (Age 57, Pay $528.8k)
  • Mr. Mark Dermody, Interim CIO
  • James Staveley, VP of Investor Relations
  • Marc Perkins, Gen. Counsel & Company Sec.
  • Dr. Cheri L. Walker, Sr. VP of Corp. Devel.
  • Mr. Nick Skinner, Sr. VP of HR
  • Mr. Mark Bushfield, Sr. VP of Research & Innovation
  • Ms. Kirstie Speck BBusSc, Head of Consumer Insights
  • Ms. Yvonne Chien, Sr. VP of Customer Experience

Who are some of Abcam's key competitors?

What other stocks do shareholders of Abcam own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abcam investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), HSBC (HSBA), Royal Dutch Shell (RDSA) and Centrica (CNA).

What is Abcam's stock symbol?

Abcam trades on the London Stock Exchange (LON) under the ticker symbol "ABC."

How do I buy shares of Abcam?

Shares of ABC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Abcam's stock price today?

One share of ABC stock can currently be purchased for approximately GBX 1,500.

How much money does Abcam make?

Abcam has a market capitalization of £3.40 billion and generates £269.30 million in revenue each year.

How many employees does Abcam have?

Abcam employs 21,500 workers across the globe.

What is Abcam's official website?

The official website for Abcam is www.abcam.com.

Where are Abcam's headquarters?

Abcam is headquartered at 330 Cambridge Science Park, CAMBRIDGE, CB4 0FL, United Kingdom.

How can I contact Abcam?

Abcam's mailing address is 330 Cambridge Science Park, CAMBRIDGE, CB4 0FL, United Kingdom. The company can be reached via phone at +44-1223-696000.


This page was last updated on 9/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.